EMA restricts high-dose cyproterone because of meningioma risk

  • European Medicines Agency
  • 14 Feb 2020

  • curated by Pavankumar Kamat
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The safety committee of the European Medicines Agency (EMA) has recommended restricting products containing cyproterone with daily doses of 10 mg because of meningioma risk.

Why this matters

  • In July 2019, the EMA's Pharmacovigilance Risk Assessment Committee initiated a safety review after a request from France based on results showing a cumulative dose-dependent association between cyproterone acetate and meningioma.

Key points

  • The new guidance strengthens warnings introduced in 2009 about the risk for noncancerous meningeal tumors.
  • EMA recommends use of products containing cyproterone 10 mg daily only when other options, including lower doses, have failed for treatment of androgen-dependent conditions such as hirsutism, alopecia, acne, and seborrhea.
  • Once higher doses show effect, the dose should be gradually decreased to the lowest effective dose.
  • Companies marketing these products must conduct a study to assess clinician awareness of meningioma risk and how to avoid it.
  • Meningioma risk is low (1-10 per 10,000 population), and most cases have been reported after prolonged exposure to high cyproterone doses (25 mg daily).
  • There is no change in the use of these products in the antiandrogen treatment of prostate cancer or for low-dose cyproterone in combination with estrogens for acne, hirsutism, contraception, or hormone replacement.